Iovance Biotherapeutics

Iovance Biotherapeutics appoints Timothy Morris CFO

Thursday, August 10, 2017

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced the appointment of Timothy E. Morris as Chief Financial Officer of the company, effective August 14, 2017. Morris has over 30 years of strategic financial and operating experience in the biotechnology sector.

[Read More]

Lion Biotechnologies changes name to Iovance Biotherapeutics

Monday, July 3, 2017

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies to Iovance Biotherapeutics. The company’s new NASDAQ ticker symbol “IOVA” will be effective at the open of the market on June 28, 2017. The former ticker symbol “LBIO” will remain effective through the market close today, June 27, 2017. The new website for Iovance Biotherapeutics is www.iovance.com.

[Read More]